Thomas Michael Maynard

Thomas Michael Maynard

Auto-generated profile, based on publicly available information

Thomas Michael Maynard

Fralin Biomedical Research Institute at Virginia Tech Carilion 2 Riverside Circle, Roanoke, Virginia, 24016, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Neuron
Verified
Journal Article
Closed access
MLMaria K. Lehtinen
Maria K. Lehtinen
MZMauro W. Zappaterra
Mauro W. Zappaterra
XCXi Chen
Xi Chen
YYYawei J. Yang
Yawei J. Yang
AHAnthony D. Hill
Anthony D. Hill
CWChristopher A. Walsh
Christopher A. Walsh

21 March 2017 in Molecular Psychiatry
Verified
Journal Article
Open access
PSP Steullet
P Steullet
JCJ-H Cabungcal
J-H Cabungcal
JCJ Coyle
J Coyle
MDM Didriksen
M Didriksen
KGK Gill
K Gill
KDK Q Do
K Q Do
Parvalbumin inhibitory interneurons (PVIs) are crucial for maintaining proper excitatory/inhibitory balance and high-frequency neuronal synchronization. Their activity supports critical developmental trajectories, sensory and cognitive processing, and social behavior. Despite heterogeneity in the etiology across schizophrenia and autism spectrum disorder, PVI circuits are altered in these psychiatric disorders. Identifying mechanism(s) underlying PVI deficits is essential to establish treatments targeting in particular cognition. On the basis of published and new data, we propose oxidative stress as a common pathological mechanism leading to PVI impairment in schizophrenia and some forms of autism. A series of animal models carrying genetic and/or environmental risks relevant to diverse etiological aspects of these disorders show PVI deficits to be all accompanied by oxidative stress in the anterior cingulate cortex. Specifically, oxidative stress is negatively correlated with the integrity of PVIs and the extracellular perineuronal net enwrapping these interneurons. Oxidative stress may result from dysregulation of systems typically affected in schizophrenia, including glutamatergic, dopaminergic, immune and antioxidant signaling. As convergent end point, redox dysregulation has successfully been targeted to protect PVIs with antioxidants/redox regulators across several animal models. This opens up new perspectives for the use of antioxidant treatments to be applied to at-risk individuals, in close temporal proximity to environmental impacts known to induce oxidative stress.

1 January 2001 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
TMThomas M. Maynard
Thomas M. Maynard
LSLinmarie Sikich
Linmarie Sikich
JLJeffrey A. Lieberman
Jeffrey A. Lieberman
ALAnthony-Samuel LaMantia
Anthony-Samuel LaMantia
To account for the complex genetics, the developmental biology, and the late adolescent/early adulthood onset of schizophrenia, the “two-hit” hypothesis has gained increasing attention. In this model, genetic or environmental factors disrupt early central nervous system (CNS) development. These early disruptions produce long-term vulnerability to a “second hit” that then leads to the onset of schizophrenia symptoms. The cell-cell signaling pathways involved in nonaxial induction, morphogenesis, and differentiation in the brain, as well as in the limbs and face, could be targets for a “first hit” during early development. These same pathways, redeployed for neuronal maintenance rather than morphogenesis, may be targets for a “second hit” in the adolescent or adult brain. Furthermore, dysregulation of cell-cell signaling by a “first hit” may prime the CNS for a pathologic response to a “second hit” via the same signaling pathway. Thus, parallel disruption of cell-cell signaling in both the developing and the mature CNS provides a plausible way of integrating genetic, developmental, and environmental factors that contribute to vulnerability and pathogenesis in schizophrenia.

1 July 2000 in Development
Verified
Journal Article
Open access
PDF file
YWYoshio Wakamatsu
Yoshio Wakamatsu
TMThomas M. Maynard
Thomas M. Maynard
JWJames A. Weston
James A. Weston
Avian trunk neural crest cells give rise to a variety of cell types including neurons and satellite glial cells in peripheral ganglia. It is widely assumed that crest cell fate is regulated by environmental cues from surrounding embryonic tissues. However, it is not clear how such environmental cues could cause both neurons and glial cells to differentiate from crest-derived precursors in the same ganglionic locations. To elucidate this issue, we have examined expression and function of components of the NOTCH signaling pathway in early crest cells and in avian dorsal root ganglia. We have found that Delta1, which encodes a NOTCH ligand, is expressed in early crest-derived neuronal cells, and that NOTCH1 activation in crest cells prevents neuronal differentiation and permits glial differentiation in vitro. We also found that NUMB, a NOTCH antagonist, is asymmetrically segregated when some undifferentiated crest-derived cells in nascent dorsal root ganglia undergo mitosis. We conclude that neuron-glia fate determination of crest cells is regulated, at least in part, by NOTCH-mediated lateral inhibition among crest-derived cells, and by asymmetric cell division.

1 May 1999 in Neuron
Verified
Journal Article
Closed access
YWYoshio Wakamatsu
Yoshio Wakamatsu
TMThomas M Maynard
Thomas M Maynard
SJSonya U Jones
Sonya U Jones
JWJames A Weston
James A Weston

1 September 2012 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MMM. Chiara Manzini
M. Chiara Manzini
DTDimira E. Tambunan
Dimira E. Tambunan
RHR. Sean Hill
R. Sean Hill
TYTim W. Yu
Tim W. Yu
TMThomas M. Maynard
Thomas M. Maynard
CWChristopher A. Walsh
Christopher A. Walsh